<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR89920-0112 </DOCNO><DOCID>fr.9-20-89.f2.A1111</DOCID><TEXT><ITAG tagnum="94"><ITAG tagnum="69"><ITAG tagnum="50">DEPARTMENT OF JUSTICE</ITAG><ITAG tagnum="18">Drug Enforcement Administration</ITAG><ITAG tagnum="56">Controlled Substances; Proposed Aggregate Production Quotas for 1990</ITAG><ITAG tagnum="10"><T2>AGENCY:</T2> Drug Enforcement Administration, Justice.</ITAG><ITAG tagnum="10"><T2>ACTION:</T2> Notice of proposed aggregate production quotas for 1990. </ITAG><ITAG tagnum="10"><T2>SUMMARY:</T2> This notice proposes initial 1990 aggregate productionquotas for substances in Schedules I and II of the Controlled SubstancesAct.</ITAG><ITAG tagnum="10"><T2>DATE:</T2> Comments or objections should be received on or before October20, 1989.</ITAG><ITAG tagnum="10"><T2>ADDRESS:</T2> Send comments or objections to the Administrator, DrugEnforcement Administration, Washington, DC 20537, Attn: DEA Federal RegisterRepresentative. (CCR).</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT:</T2> Howard McClain, Jr., Chief, DrugControl Section, Drug Enforcement Administration, Washington, DC 20537,(202) 307-7183.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION:</T2> Section 306 of the Controlled SubstancesAct (21 U.S. Code, 826) requires that the Attorney General establish aggregateproduction quotas for all controlled substances listed in Schedules I andII. This responsibility has been delegated to the Administrator of theDrug Enforcement Administration by andSection; 0.100 of Title 28 of the Codeof Federal Regulations. The quotas are to provide adequate supplies of each substance for: (1)The estimated medical, scientific, research, and industrial needs of theUnited States; (2) lawful export requirements; and (3) the establishmentand maintenance of reserve stocks. In determining the below listed proposed 1990 aggregate production quotas,the Administrator considered the following factors: (1) Total actual 1988and estimated 1989 and 1990 net disposals of each substance by all manufacturers;(2) estimates of inventories of each substance and of any substance manufacturedfrom it and trends in accumulation of such inventories; and (3) projecteddemand as indicated by procurement quota applications filed pursuant toandSection; 1303.12 of Title 21 of the Code of Federal Regulations. Pursuant to andSection; 1303.23(c) of Title 21 of the Code of Federal Regulations,the Administrator of the Drug Enforcement Administration will in early1990 adjust individual manufacturing quotas allocated for the year basedupon 1989 year-end inventory and actual 1989 disposition data suppliedby quota recipients for each basic class of Schedule I or II controlledsubstance. Based upon consideration of the above factors, the Administrator of theDrug Enforcement Administration hereby proposes that aggregate productionquotas for 1990 for the following controlled substances, expressed in gramsof anhydrous acid or base, be established as follows:<ITAG tagnum="110"><C>2,L2,tp0,i1,s25,10</C>  <H1>Basic class</H1><H1>Proposed 1990 quotas</H1> Schedule I:<ITAG tagnum="2">2,5-Dimethoxyamphetamine<D>15,300,000 </D></ITAG><ITAG tagnum="2">Lysergic Acid Diethylamide<D>11 </D></ITAG><ITAG tagnum="2">3,4-Methylenedioxyamphetamine<D>7 </D></ITAG><ITAG tagnum="2">3,4-Methylenedioxymethamphetamine<D>12 </D></ITAG><ITAG tagnum="2">Tetrahydrocannabinols<D>13,000 </D></ITAG><ITAG tagnum="2">Psilocyn<D>2 </D></ITAG><ITAG tagnum="2">Psilocybin<D>2 </D></ITAG><ITAG tagnum="2">4-Methylaminorex<D>5 </D></ITAG><ITAG tagnum="2">Methaqualone<D>2 </D></ITAG><ITAG tagnum="2">N-Hydroxy-3,4-Methylenedioxyamphetamine<D>2 </D></ITAG><ITAG tagnum="2">N-Ethylamphetamine<D>5</D></ITAG>Schedule II: <ITAG tagnum="2">Alfentanil<D>5,000 </D></ITAG><ITAG tagnum="2">Amobarbital<D>596,000 </D></ITAG><ITAG tagnum="2">Amphetamine<D>279,000 </D></ITAG><ITAG tagnum="2">Cocaine<D>600,000 </D></ITAG><ITAG tagnum="2">Codeine (for sale)<D>53,518,000 </D></ITAG><ITAG tagnum="2">Codeine (for conversion)<D>5,093,000 </D></ITAG><ITAG tagnum="2">Desoxyephedrine<D>1,252,000</D></ITAG>1,252,000 grams of levodesoxyephedrine for use in a noncontrolled, nonprescriptionproduct and 0.0 grams for methamphetamine.<ITAG tagnum="2">Dextropropoxyphene<D>79,955,000 </D></ITAG><ITAG tagnum="2">Dihydrocodeine<D>435,000 </D></ITAG><ITAG tagnum="2">Diphenoxylate<D>882,000 </D></ITAG><ITAG tagnum="2">Ecgonine (for conversion)<D>650,000 </D></ITAG><ITAG tagnum="2">Fentanyl<D>25,900 </D></ITAG><ITAG tagnum="2">Hydrocodone<D>3,026,000 </D></ITAG><ITAG tagnum="2">Hydromorphone<D>223,000 </D></ITAG><ITAG tagnum="2">Levorphanol<D>10,700 </D></ITAG><ITAG tagnum="2">Meperidine<D>10,019,000 </D></ITAG><ITAG tagnum="2">Methadone<D>1,441,000 </D></ITAG><ITAG tagnum="2">Methadone Intermediate (4-Cyano-2-dimethylamino-4,4-diphenylbutane)<D>1,802,000 </D></ITAG><ITAG tagnum="2">Methamphetamine (for conversion)<D>1,206,000 </D></ITAG><ITAG tagnum="2">Methylphenidate<D>2,262,000 </D></ITAG><ITAG tagnum="2">Mixed Alkaloids of Opium<D>7,000 </D></ITAG><ITAG tagnum="2">Morphine (for sale)<D>3,841,000 </D></ITAG><ITAG tagnum="2">Morphine (for conversion)<D>59,243,000 </D></ITAG><ITAG tagnum="2">Opium (tinctures, extracts, etc. expressed in terms of USP powderedopium)<D>1,337,000 </D></ITAG><ITAG tagnum="2">Oxycodone (for sale)<D>2,427,000 </D></ITAG><ITAG tagnum="2">Oxycodone (for conversion)<D>5,600 </D></ITAG><ITAG tagnum="2">Oxymorphone<D>2,500 </D></ITAG><ITAG tagnum="2">Pentobarbital<D>11,296,000 </D></ITAG><ITAG tagnum="2">Phencyclidine<D>25 </D></ITAG><ITAG tagnum="2">Phenylacetone (for conversion)<D>684,000 </D></ITAG><ITAG tagnum="2">1-Piperidinocyclohexanecarbonitrile (for conversion)<D>40 </D></ITAG><ITAG tagnum="2">Secobarbital<D>583,000 </D></ITAG><ITAG tagnum="2">Sufentanil<D>400 </D></ITAG><ITAG tagnum="2">Thebaine<D>6,125,000</D></ITAG></ITAG> All interested persons are invited to submit their comments and objectionsin writing regarding this proposal. A person may object to or comment onone of the above-mentioned substances without filing comments or objectionsregarding the others. Comments and objections should be submitted to theAdministrator, Drug Enforcement Administration, United States Departmentof Justice, Washington, DC 20537, Attn: DEA Federal Representative (CCR)and must be received by (30 days from date of publication). If a personbelieves that one or more issues warrant a hearing, a statement to thateffect with a summary of reasons for such belief should be submitted. In the event that comments or objections to this proposal raise one ormore issues which the Administrator finds warrant a hearing, the Administratorshall cause such hearing to be convened pursuant to the provisions of Title21 of the Code of Federal Regulations, andSection; 1303.31(a). Pursuant to Section (3)(c)(3) and 3(e)(2)(C) of Executive Order 12291,the Director of the Office of Management and Budget has been consultedwith respect to these proceedings. This action has been analyzed in accordance with the principles and criteriacontained in Executive Order 12612, and it has been determined that thismatter does not have sufficient federalism implications to warrant thepreparation of a Federalism Assessment. The Administrator hereby certifies that this matter will have no significantimpact upon small entities within the meaning of and intent of the RegulatoryFlexibility Act, 5 U.S. Code, 601, et seq. The establishment of annualaggregate production quotas for Schedules I and II controlled substancesis mandated by law and by international commitments of the United States.Such quotas impact predominantly upon major manufacturers of the affectedcontrolled substances.<ITAG tagnum="21">Dated: August 21, 1989.</ITAG><ITAG tagnum="6">John C. Lawn,</ITAG><ITAG tagnum="4">Administrator, Drug Enforcement Administration.</ITAG><ITAG tagnum="40">[FR Doc. 89-22114 Filed 9-19-89; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4410-09-M</ITAG></ITAG></ITAG></ITAG></TEXT></DOC>